In September and October, we proudly celebrated the rich heritage of our Latino/Hispanic colleagues. Our Employee Resource Group, HOLA, is leading the way across Merck KGaA, Darmstadt, Germany with initiatives to honor #HispanicHeritageMonth in the U.S. and beyond. Sebastián Arana A., Alessandra Richardson, PhD, CMPP, Andrea Valencia, Global EMBA EMD Serono EMD Electronics
MilliporeSigma
生物技术研究
Burlington,MA 202,561 位关注者
Together, we impact life and health with science.
关于我们
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in. We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities. Our vision is a world where our innovative products, services and digital offerings help create solutions for people globally and a sustainable future for generations to come. The life science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the US and Canada. Merck KGaA, Darmstadt, Germany is a global science and technology company with around 60,000 employees in more than 66 countries. Intended only for US/CA visitors.
- 网站
-
https://www.sigmaaldrich.com
MilliporeSigma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 超过 10,001 人
- 总部
- Burlington,MA
- 类型
- 上市公司
- 创立
- 1668
- 领域
- Life Science Research、Drug Discovery & Development、Lab Filtration、Lab Water、Bioscience、Upstream & Downstream Bioprocessing、BioMonitoring、Lab Solutions、Life Sciences和Process Solutions
地点
-
主要
400 Summit Drive
US,MA,Burlington,01803
MilliporeSigma员工
动态
-
Hear from experts Melisa Wilson and Alexandra Fajardo as they explain biosafety testing, why it's essential in drug production, and how the opening of our new Rockville biosafety testing site will help foster even faster innovations.
-
Join us on LinkedIn for a live and interactive panel discussion to explore the future of ADCs in cancer treatment. The discussion will focus on recent advancements in technology and integration with other therapies. Key topics will include innovations in antibody engineering, linker chemistry, payload selection, the role of biomarkers, and challenges in manufacturing. This event is an excellent opportunity for experts, researchers, clinicians, and industry professionals to gain insights into the latest developments and future directions of ADCs. Click Attend to RSVP.
Future Directions: Next-GenerationADCs & Combination Therapies
www.dhirubhai.net
-
Test yourself! One challenge drug makers face is the poor solubility of active pharmaceutical ingredients (APIs). When taken by a patient, the API within the drug product should be soluble, meaning it should absorb into the body. And yet, 70% of drugs in development are poorly soluble. Knowing this, which of the below techniques do drug makers use to combine API with one or more compounds to overcome solubility challenges? Hint: Find out how our AI-based mPredict service can expedite your drug development process and help you overcome solubility issues. https://ms.spr.ly/6043mNhpS?
此处无法显示此内容
在领英 APP 中访问此内容等
-
Join us next week for an interactive discussion on the future of ADCs in cancer treatment! Our panel of experts will cover advancements in antibody engineering, linker chemistry, biomarkers, and more. Register for the free event here: https://ms.spr.ly/6048mIL6y
-
BIG news! We just opened our new €290 million biosafety testing facility in Rockville, USA. Our largest biosafety testing investment ever, the new space will help ensure the medicines we take are safe and effective. This new hub brings our testing teams in Rockville together into a single facility, fostering even more innovation, faster. The space enables advances in automation and digitalization and features novel solutions like the Blazar CHO Animal Origin Free panel, cutting viral test timelines by 60%. Read how we are ensuring the safety of the world's medicines for patients here: https://ms.spr.ly/6041mx9kX
-
70% of drugs in development suffer from poor solubility, impacting their ability to be formulated. The solution? AI and Co-crystallization. Crystallizing a drug compound with a co-former can drastically improve solubility, but identifying the optimal co-former takes time and resources. Find out how David Lüdeker is supporting scientists by harnessing the power of AI to accelerate drug formulation.
-
?? Are you smarter than an 11-year-old? At the 2024 Curiosity Cube, students are diving into sustainability by exploring the life cycle of a T-shirt—from the materials used to the production processes that impact our planet. By the time they leave, they have learned about sustainable choices and can answer this question. Can you?
此处无法显示此内容
在领英 APP 中访问此内容等